Abstract
Attention deficit hyperactivity disorder (ADHD) is frequently comorbid with borderline personality disorder (BPD). However, few studies have examined how comorbid BPD–ADHD patients, treated or not with methylphenidate (MPH), respond to psychotherapy compared to non-comorbid BPD patients. In this perspective, we used a naturalistic study to compare, during a month-long intensive dialectical behaviour therapy (DBT), the clinical course of BPD patients and comorbid BPD–ADHD patients who were treated or untreated with MPH. Out of the 158 BPD patients recruited, 59 had adult ADHD as a comorbidity; among these, 29 underwent a treatment with MPH or des-methylphenidate, while the 30 others did not. MPH treatment was given non-randomly and only when ADHD was considered to be hampering the capacity of the subjects to follow the therapy. Patients completed the following forms upon admission and after 1 month of treatment: the adult ADHD Self-Report Scale (ASRS v.1.1), the Barratt Impulsiveness Scale (BIS-10), the State–Trait Anger Expression (STAXI), the Beck Depression Inventory II (BDI-II), and the Beck Hopelessness Scale. At baseline, comorbid BPD–ADHD patients showed significantly higher impulsiveness than BPD patients. In the entire sample, there was a significant decrease in all dimensions ranging from small to large effect sizes during the 4-week intensive DBT. BPD–ADHD patients who were undergoing MPH treatment showed a significantly improved response to DBT treatment for Trait–State Anger scores, motor impulsiveness, depression severity, and ADHD severity, when compared to those without stimulant medication. This study outlines the importance of systematically screening BPD patients for ADHD, since a MPH-based treatment will improve the symptoms of patients who are comorbid for BPD and ADHD. Due to the non-random allocation of subjects, more severely affected patients were more readily placed on MPH; this suggests that the more severe the ADHD symptoms, the greater the chance for the patient of being treated.
Similar content being viewed by others
References
American Psychiatric Association (2001) Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. Am J Psychiatry 158(10 Suppl):1–52
Bateman A, Fonagy P (2010) Mentalization based treatment for borderline personality disorder. World Psychiatry 9(1):11–15
Bayle FJ, Bourdel MC, Caci H et al (2000) Factor analysis of french translation of the Barratt impulsivity scale (BIS-10). Can J Psychiatry 45(2):156–165
Beck AT, Weissman A, Lester D et al (1974) The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol 42(6):861–865
Beck AT, Steer RA, Ball R et al (1996) Comparison of beck depression inventories-IA and -II in psychiatric outpatients. J Pers Assess 67(3):588–597
Bellino S, Paradiso E, Bozzatello P et al (2010) Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol 24(3):333–339
Davids E, Gastpar M (2005) Attention deficit hyperactivity disorder and borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 29(6):865–877
Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 71(6):754–763
First M, Gibbon M, Spitzer R et al (1994) Structured Clinical Interview for DSM-IV personality disorders (SCID-II). American Psychiatric Association, Washington, DC
Fossati A, Novella L, Donati D et al (2002) History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Compr Psychiatry 43(5):369–377
Golubchik P, Sever J, Zalsman G et al (2008) Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol 23(4):228–231
Herpertz S, Gretzer A, Steinmeyer EM et al (1997) Affective instability and impulsivity in personality disorder. Results of an experimental study. J Affect Disord 44(1):31–37
Herpertz SC, Kunert HJ, Schwenger UB et al (1999) Affective responsiveness in borderline personality disorder: a psychophysiological approach. Am J Psychiatry 156(10):1550–1556
Ingenhoven T, Lafay P, Rinne T et al (2010) Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry 71(1):14–25
Jacob GA, Gutz L, Bader K et al (2010) Impulsivity in borderline personality disorder: impairment in self-report measures, but not behavioral inhibition. Psychopathology 43(3):180–188
Lampe K, Konrad K, Kroener S et al (2007) Neuropsychological and behavioural disinhibition in adult ADHD compared to borderline personality disorder. Psychol Med 37(12):1717–1729
Lieb K, Zanarini MC, Schmahl C et al (2004) Borderline personality disorder. Lancet 364(9432):453–461
Linehan MM (1993) Cognitive-behavioral treatment of borderline personality disorder. The Guilford Press, New York
Lynch TR, Trost WT, Salsman N et al (2007) Dialectical behavior therapy for borderline personality disorder. Annu Rev Clin Psychol 3:181–205
Maneeton N, Maneeton B, Intaprasert S et al (2014) A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 10:1439–1449
Matthies S, Philipsen A, Lackner HK et al (2014) Regulation of sadness via acceptance or suppression in adult attention deficit hyperactivity disorder (ADHD). Psychiatry Res 220(1–2):461–467
McIntyre RS, Alsuwaidan M, Soczynska JK et al (2013) The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol 28(5):421–427
Mendonca DA, Menezes K, Jog MS (2007) Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 22(14):2070–2076
Nigg JT (2001) Is ADHD a disinhibitory disorder? Psychol Bull 127(5):571–598
Perroud N, Salzmann A, Saiz PA et al (2010a) Rare genotype combination of the serotonin transporter gene associated with treatment response in severe personality disorder. Am J Med Genet B Neuropsychiatr Genet 153B(8):1494–1497
Perroud N, Uher R, Dieben K et al (2010b) Predictors of response and drop-out during intensive dialectical behavior therapy. J Pers Disord 24(5):634–650
Perroud N, Nicastro R, Jermann F et al (2012) Mindfulness skills in borderline personality disorder patients during dialectical behavior therapy: preliminary results. Int J Psychiatry Clin Pract 16(3):189–196
Perroud N, Cordera P, Zimmermann J et al (2014) Comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar disorder in a specialized mood disorders outpatient clinic. J Affect Disord 168:161–166
Philipsen A (2006) Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. Eur Arch Psychiatry Clin Neurosci 256(Suppl 1):i42–i46
Philipsen A, Limberger MF, Lieb K et al (2008) Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry 192(2):118–123
Philipsen A, Feige B, Hesslinger B et al (2009) Borderline typical symptoms in adult patients with attention deficit/hyperactivity disorder. Atten Defic Hyperact Disord 1(1):11–18
Prada P, Hasler R, Baud P et al (2014) Distinguishing borderline personality disorder from adult attention deficit/hyperactivity disorder: a clinical and dimensional perspective. Psychiatry Res 217(1–2):107–114
Preisig M, Fenton BT, Matthey ML et al (1999) Diagnostic interview for genetic studies (DIGS): inter-rater and test–retest reliability of the French version. Eur Arch Psychiatry Clin Neurosci 249(4):174–179
Ravindran AV, Kennedy SH, O’Donovan MC et al (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69(1):87–94
Romo L, Legauffre C, Mille S et al (2010) Psychometric properties of the French version of the Wender Utah Rating Scale and Brown’s Attention Deficit Disorders Scale for adults. Encephale 36(5):380–389
Shaw P, Stringaris A, Nigg J et al (2014) Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry 171(3):276–293
Sinita E, Coghill D (2014) The use of stimulant medications for non-core aspects of ADHD and in other disorders. Neuropharmacology 87:161–172
Skodol AE, Gunderson JG, Pfohl B et al (2002) The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 51(12):936–950
Spielberger C (1998) State-trait anger expression inventory, research edition. Professional Manual. Psychological Assessment Resources, Odessa, FL
Stoffers JM, Vollm BA, Rucker G et al (2012) Psychological therapies for people with borderline personality disorder. Cochrane Database Syst Rev 8:CD005652
Trivedi MH, Cutler AJ, Richards C et al (2013) A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J Clin Psychiatry 74(8):802–809
van Dijk FE, Lappenschaar M, Kan CC et al (2012) Symptomatic overlap between attention-deficit/hyperactivity disorder and borderline personality disorder in women: the role of temperament and character traits. Compr Psychiatry 53(1):39–47
van Reekum R, Links PS (1994) N of 1 study: methylphenidate in a patient with borderline personality disorder and attention deficit hyperactivity disorder. Can J Psychiatry 39(3):186–187
Volkow ND, Swanson JM (2013) Clinical practice: adult attention deficit-hyperactivity disorder. N Engl J Med 369(20):1935–1944
Ward MF, Wender PH, Reimherr FW (1993) The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 150(6):885–890
Yeomans FE, Levy KN, Caligor E (2013) Transference-focused psychotherapy. Psychotherapy 50(3):449–453
Zanarini MC (2000) Childhood experiences associated with the development of borderline personality disorder. Psychiatr Clin North Am 23(1):89–101
Zanarini MC, Williams AA, Lewis RE et al (1997) Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 154(8):1101–1106
Zanarini MC, Frankenburg FR, Dubo ED et al (1998) Axis I comorbidity of borderline personality disorder. Am J Psychiatry 155(12):1733–1739
Acknowledgments
We would like to thank Gérald Bouillault, Jean-Jacques Kunckler, Sophie Blin, Charlotte Germond, Venus Kaby, Karen Dieben and Caroline Waeber for their help in recruiting and assessing patients.
Conflict of interest
Authors have no personal affiliations or financial relationships with any commercial interest to disclose in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prada, P., Nicastro, R., Zimmermann, J. et al. Addition of methylphenidate to intensive dialectical behaviour therapy for patients suffering from comorbid borderline personality disorder and ADHD: a naturalistic study. ADHD Atten Def Hyp Disord 7, 199–209 (2015). https://doi.org/10.1007/s12402-015-0165-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12402-015-0165-2